184 results on '"Latimer, Nicholas R."'
Search Results
2. Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling
3. Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know
4. Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments
5. A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study
6. Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters
7. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival
8. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum
9. Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom
10. Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals
11. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making
12. Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting
13. Perils of randomised controlled trial survival extrapolation assuming treatment effect waning: why the distinction between marginal and conditional estimates matters
14. Evaluation of flexible parametric relative survival approaches for enforcing long-term constraints when extrapolating all-cause survival
15. Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop
16. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
17. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing–Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study
18. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
19. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial
20. The role of treatment crossover adjustment methods in the context of economic evaluation
21. A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment
22. Methods for Analysis of Trials with Changes from Randomized Treatment
23. A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis
24. sj-docx-1-mdm-10.1177_0272989X231168618 – Supplemental material for A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment
25. sj-docx-1-mdm-10.1177_0272989X231184247 – Supplemental material for Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial
26. Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
27. Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness
28. Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
29. Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials
30. Not cost-effective at zero price: valuing and paying for combination therapies in cancer
31. sj-pdf-1-cre-10.1177_0269215520975348 – Supplemental material for Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation
32. sj-pdf-6-mdm-10.1177_0272989X20978958 – Supplemental material for Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer
33. sj-pdf-8-mdm-10.1177_0272989X20978958 – Supplemental material for Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer
34. sj-pdf-2-mdm-10.1177_0272989X20978958 – Supplemental material for Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer
35. sj-pdf-5-mdm-10.1177_0272989X20978958 – Supplemental material for Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer
36. sj-pdf-3-mdm-10.1177_0272989X20978958 – Supplemental material for Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer
37. sj-pdf-1-mdm-10.1177_0272989X20978958 – Supplemental material for Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer
38. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer
39. Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation
40. Modelling the Cost-Effectiveness of Alcohol Screening and Brief Interventions in Primary Care in England
41. Inconsistencies in NICE guidance for acupuncture: reanalysis and discussion
42. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
43. Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation.
44. Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT
45. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
46. The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight
47. A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis
48. Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
49. Behavioural Activation Therapy for Depression after Stroke (BEADS): a study protocol for a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression
50. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.